AT506632A1 - Behandlung von tumorerkrankungen - Google Patents

Behandlung von tumorerkrankungen Download PDF

Info

Publication number
AT506632A1
AT506632A1 AT0056608A AT5662008A AT506632A1 AT 506632 A1 AT506632 A1 AT 506632A1 AT 0056608 A AT0056608 A AT 0056608A AT 5662008 A AT5662008 A AT 5662008A AT 506632 A1 AT506632 A1 AT 506632A1
Authority
AT
Austria
Prior art keywords
ace2
tumor
cancer
use according
activity
Prior art date
Application number
AT0056608A
Other languages
German (de)
English (en)
Original Assignee
Apeiron Biolog Forschungs Und
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apeiron Biolog Forschungs Und filed Critical Apeiron Biolog Forschungs Und
Priority to AT0056608A priority Critical patent/AT506632A1/de
Priority to PT97307714T priority patent/PT2274005E/pt
Priority to PCT/AT2009/000136 priority patent/WO2009124330A2/de
Priority to CA2720616A priority patent/CA2720616C/en
Priority to ES09730771T priority patent/ES2425308T3/es
Priority to DK09730771.4T priority patent/DK2274005T3/da
Priority to AU2009235931A priority patent/AU2009235931B2/en
Priority to EP13162709.3A priority patent/EP2644203A1/de
Priority to US12/937,029 priority patent/US8946162B2/en
Priority to PL09730771T priority patent/PL2274005T3/pl
Priority to NZ588435A priority patent/NZ588435A/xx
Priority to EP09730771.4A priority patent/EP2274005B1/de
Priority to JP2011503304A priority patent/JP5650639B2/ja
Publication of AT506632A1 publication Critical patent/AT506632A1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/17—Metallocarboxypeptidases (3.4.17)
    • C12Y304/17023—Angiotensin-converting enzyme 2 (3.4.17.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT0056608A 2008-04-09 2008-04-09 Behandlung von tumorerkrankungen AT506632A1 (de)

Priority Applications (13)

Application Number Priority Date Filing Date Title
AT0056608A AT506632A1 (de) 2008-04-09 2008-04-09 Behandlung von tumorerkrankungen
PT97307714T PT2274005E (pt) 2008-04-09 2009-04-07 Tratamento de doenças tumorais pela enzima conversora de angiotensina 2 (ace2)
PCT/AT2009/000136 WO2009124330A2 (de) 2008-04-09 2009-04-07 Behandlung von tumorerkrankungen
CA2720616A CA2720616C (en) 2008-04-09 2009-04-07 Treatment of tumours
ES09730771T ES2425308T3 (es) 2008-04-09 2009-04-07 Tratamiento de enfermedades tumorales mediante enzima convertidora de angiotensina 2 (ACE2)
DK09730771.4T DK2274005T3 (da) 2008-04-09 2009-04-07 Behandling af tumorsygdomme med angiotensin konverterende enzym 2 (ACE2)
AU2009235931A AU2009235931B2 (en) 2008-04-09 2009-04-07 Treatment of tumors
EP13162709.3A EP2644203A1 (de) 2008-04-09 2009-04-07 Behandlung von Tumorerkrankungen
US12/937,029 US8946162B2 (en) 2008-04-09 2009-04-07 Treatment of tumors
PL09730771T PL2274005T3 (pl) 2008-04-09 2009-04-07 Leczenie chorób nowotworowych z użyciem konwertazy angiotensyny 2 (ace2)
NZ588435A NZ588435A (en) 2008-04-09 2009-04-07 Use of a polypeptide with an angiotensin-converting enzyme 2 (ACE2) activity for treating tumours (with the exception of lung cancer)
EP09730771.4A EP2274005B1 (de) 2008-04-09 2009-04-07 Behandlung von tumorerkrankungen durch angiotensin konvertierendes enzym 2 (ace2)
JP2011503304A JP5650639B2 (ja) 2008-04-09 2009-04-07 腫瘍疾患の治療

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0056608A AT506632A1 (de) 2008-04-09 2008-04-09 Behandlung von tumorerkrankungen

Publications (1)

Publication Number Publication Date
AT506632A1 true AT506632A1 (de) 2009-10-15

Family

ID=41130316

Family Applications (1)

Application Number Title Priority Date Filing Date
AT0056608A AT506632A1 (de) 2008-04-09 2008-04-09 Behandlung von tumorerkrankungen

Country Status (12)

Country Link
US (1) US8946162B2 (cg-RX-API-DMAC7.html)
EP (2) EP2644203A1 (cg-RX-API-DMAC7.html)
JP (1) JP5650639B2 (cg-RX-API-DMAC7.html)
AT (1) AT506632A1 (cg-RX-API-DMAC7.html)
AU (1) AU2009235931B2 (cg-RX-API-DMAC7.html)
CA (1) CA2720616C (cg-RX-API-DMAC7.html)
DK (1) DK2274005T3 (cg-RX-API-DMAC7.html)
ES (1) ES2425308T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ588435A (cg-RX-API-DMAC7.html)
PL (1) PL2274005T3 (cg-RX-API-DMAC7.html)
PT (1) PT2274005E (cg-RX-API-DMAC7.html)
WO (1) WO2009124330A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019106085A1 (en) * 2017-11-29 2019-06-06 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft Methods for modulating pigmentation by angiotensin-converting enzyme 2 modulation

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT505262A1 (de) * 2007-06-12 2008-12-15 Apeiron Biolog Forschungs Und Rekombinantes ace2 polypeptid
EP2859343B1 (en) * 2012-06-06 2019-10-23 Attoquant Diagnostics GmbH Method for measurement of peptidic degradation products of a proteolytic cascade in blood samples
US8557958B1 (en) 2012-06-18 2013-10-15 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of diabetes
US8633158B1 (en) 2012-10-02 2014-01-21 Tarix Pharmaceuticals Ltd. Angiotensin in treating brain conditions
EP2943216B1 (en) * 2013-01-14 2019-05-01 Apeiron Biologics AG Modified ace2 polypeptides
EP3650020A1 (en) * 2013-12-11 2020-05-13 Alterras Therapeutics GmbH Compositions and methods for the treatment of diseases related to the renin-angiotensin-system
US9333233B2 (en) 2014-02-25 2016-05-10 Tarix Pharmaceuticals Ltd. Methods and compositions for the delayed treatment of stroke
US20200188473A1 (en) * 2017-05-02 2020-06-18 Beth Israel Deaconess Medical Center, Inc. Combination therapy for cancer
WO2021190980A1 (en) 2020-03-22 2021-09-30 Quadrucept Bio Limited Multimers for viral strain evolution
US20230181759A1 (en) * 2020-04-01 2023-06-15 Washington University Compositions for treatment of viral respiratory infections and methods of use thereof
CN112626099A (zh) * 2020-09-29 2021-04-09 清华大学 使用原核细胞发酵表达血管紧张素转化酶2的方法
WO2022184659A1 (en) 2021-03-01 2022-09-09 Quadrucept Bio Limited Antibody domains & multimers
US20250009853A1 (en) 2021-12-03 2025-01-09 Wisconsin Alumni Research Foundation Mutant ace2 proteins and methods of using same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610497B1 (en) * 1997-12-11 2003-08-26 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor
US6194556B1 (en) 1997-12-11 2001-02-27 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therfor
US6989363B1 (en) 1997-12-11 2006-01-24 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor
AU2003217783A1 (en) * 2002-02-27 2003-09-09 Wake Forest University Angiotensin-(1-7) and angiotensin-(1-7) agonists for inhibition of cancer cell growth
WO2004000367A1 (en) * 2002-06-19 2003-12-31 University Health Network Ace2 activation for treatment of heart, lung and kidney disease and hypertension
EP1374907A3 (en) 2002-06-24 2004-01-07 Ghanem Elias c/o Institut Jules Bordet Ghanem Drug transport and delivery system
EP1723962A1 (en) * 2005-05-19 2006-11-22 IMBA-Institut für Molekulare Biotechnologie GmbH Use of inhibitors of the renin-angiotensin system for the treatment of lung injuries
AT505262A1 (de) * 2007-06-12 2008-12-15 Apeiron Biolog Forschungs Und Rekombinantes ace2 polypeptid

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019106085A1 (en) * 2017-11-29 2019-06-06 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft Methods for modulating pigmentation by angiotensin-converting enzyme 2 modulation
US11337909B2 (en) 2017-11-29 2022-05-24 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft Methods for modulating pigmentation by angiotensin-converting enzyme 2 modulation

Also Published As

Publication number Publication date
NZ588435A (en) 2012-10-26
AU2009235931A1 (en) 2009-10-15
JP2011516501A (ja) 2011-05-26
DK2274005T3 (da) 2013-08-19
ES2425308T3 (es) 2013-10-14
CA2720616C (en) 2016-08-09
PT2274005E (pt) 2013-08-27
CA2720616A1 (en) 2009-10-15
WO2009124330A3 (de) 2009-12-10
EP2274005B1 (de) 2013-05-29
JP5650639B2 (ja) 2015-01-07
US8946162B2 (en) 2015-02-03
AU2009235931B2 (en) 2015-07-23
EP2644203A1 (de) 2013-10-02
PL2274005T3 (pl) 2013-12-31
US20110033524A1 (en) 2011-02-10
WO2009124330A2 (de) 2009-10-15
EP2274005A2 (de) 2011-01-19

Similar Documents

Publication Publication Date Title
EP2274005B1 (de) Behandlung von tumorerkrankungen durch angiotensin konvertierendes enzym 2 (ace2)
EP2222330B1 (de) Behandlung inflammatorischer krankheiten mit ace2
EP2937088B1 (en) Composition having tissue repairing activity and utilization thereof
US20230053881A1 (en) Neuregulin for the treatment and/or prevention of tumors of the nervous system
Mannelli et al. Neuronal alarmin IL-1α evokes astrocyte-mediated protective signals: Effectiveness in chemotherapy-induced neuropathic pain
CA2857250A1 (en) Compositions for preventing or treating adverse reactions of egfr inhibition
EP2347761A1 (en) A composition with inhibition activity on pathological angiogenesis
Zhu et al. Esculentoside A ameliorates BSCB destruction in SCI rat by attenuating the TLR4 pathway in vascular endothelial cells
KR102213878B1 (ko) Pat4를 포함하는 만성통증 질환 예방, 개선 또는 치료용 조성물
EP3581196B1 (de) Inhibitoren des transferrinrezeptor-2 zur verwendung bei der behandlung von osteoporose
Bogusławska-Duch et al. Therapeutic combination silencing VEGF and SOX10 increases the antiangiogenic effect in the mouse melanoma model B16-F10–in vitro and in vivo studies
US20250195917A1 (en) Sequential transarterial chemoembolization, stereotactic body radiotherapy, and immunotherapy (start-fit) for hepatocellular carcinoma
KR102212699B1 (ko) 유방암 예방 또는 치료용 조성물
CN119386160A (zh) 一种神经调节蛋白4在制备抗足细胞凋亡药物中的应用
Chen et al. Ribonuclease 4 is a pancreatic endogenous β cell proliferation factor
EP1340507B1 (de) Verwendung eines Fibroblastenwachstumsfaktor-Bindeproteins zur Behandlung und Diagnose von diabetischen Wundheilugnsstörungen
CN119112760A (zh) 川芎嗪水凝胶及其在提升嵌合抗原受体t细胞免疫疗法靶向杀伤三阴性乳腺癌能力中的应用
WO2023025914A1 (de) Igf-1, igfbp-2 und insulin umfassende zusammensetzungen und ihre verwendung
Mannstadt et al. Molecular interactions of FGF23 and PTH in phosphate regulation
HK40003037A (en) Neuregulin for the treatment and/or prevention of tumors of the nervous system
HK40003037B (en) Neuregulin for the treatment and/or prevention of tumors of the nervous system
KR20120127552A (ko) 신경교종 치료를 위한 방사선 및 ｔｒａｉｌ 발현 간엽줄기세포의 조합 치료 방법

Legal Events

Date Code Title Description
REJ Rejection

Effective date: 20160515